Pfizer (PFE) Asset Writedowns and Impairment (2009 - 2026)

Pfizer (PFE) has reported Asset Writedowns and Impairment for 18 consecutive years, with $4.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment rose 4550.54% year-over-year to $4.3 billion in Q2 2026; TTM through Jun 2026 was $9.0 billion, a 413.55% increase from a year earlier, with the FY2025 full-year figure at $5.3 billion, up 24.23% from the prior year.
• Asset Writedowns and Impairment was $4.3 billion for Q2 2026 at Pfizer, up from $32.0 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $4.4 billion in Q4 2025 and troughed at $31.0 million in Q2 2022.
• A 5-year average of $964.1 million and a median of $265.0 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 4550.54% in 2026, down 90.7% in 2026.
• Over 5 years, Asset Writedowns and Impairment stood at $31.0 million in 2022, then soared by 1035.48% to $352.0 million in 2023, then jumped by 206.82% to $1.1 billion in 2024, then soared by 307.96% to $4.4 billion in 2025, then retreated by 1.84% to $4.3 billion in 2026.
• The last three Asset Writedowns and Impairment figures came in at $4.3 billion (Q2 2026), $32.0 million (Q1 2026), and $4.4 billion (Q4 2025), per Business Quant data.